1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Epiomic Epidemiology Series: Essential Thrombocythemia Forecast in 9 Major Markets 2016-2026

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Essential Thrombocythemia (ET) in 9 Major Markets

Essential Thrombocythemia (ET) or Primary Thrombocythemia, is a rare, chronic myeloproliferative disorder that involves the over production of blood platelets by the bone marrow. ET is characterized by a persisting elevated platelet count >450,000/µL, with megakaryocytic hyperplasia, and patients will likely also suffer from splenomegaly and thrombotic or hemorrhagic episodes or both.
This report provides the current prevalent population for ET across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ET have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for ET include:

• Secondary myelofibrosis
• Acute myeloid leukaemia
• Anaemia
• Splenomegaly
• Hepatomegaly
• Incident thrombosis
• Deep vein thrombosis
• Pregnancy complications

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global ET’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ET and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ET’s prevalent population.
• Identify sub-populations within ET which require treatment.
• Gain an understanding of the specific markets that have the largest number of ET patients.

Table Of Contents

Epiomic Epidemiology Series: Essential Thrombocythemia Forecast in 9 Major Markets 2016-2026
Table of Contents
- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors and Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis and Clinical Course
- Key Co-morbid Conditions/Features Associated with the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Essential Thrombocythemia
- Features of Essential Thrombocythemia Patients
o Type of Thrombotic Events
o Abnormal Organ Enlargement Associated with ET
o Blood Cell Associated Conditions
o Gene Mutations in ET
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix


List of Tables

- WHO classification criteria for ET diagnosis
- Prevalence of Essential Thrombocythemia, total (000s)
- Prevalence of Essential Thrombocythemia, males (000s)
- Prevalence of Essential Thrombocythemia, females (000s)
- Type of thrombosis in Essential Thrombocythemia patients, total (000s)
- History of thrombotic event in Essential Thrombocythemia patients, total (000s)
- Site of arterial thrombosis in Essential Thrombocythemia patients, total (000s)
- Site of venous thrombosis in Essential Thrombocythemia patients, total (000s)
- Prevalence of splenomegaly in Essential Thrombocythemia, total (000s)
- Prevalence of hepatomegaly in Essential Thrombocythemia, total (000s)
- Prevalence of myelofibrosis (SMF) in Essential Thrombocythemia, total (000s)
- Prevalence of anaemia in Essential Thrombocythemia, total (000s)
- Prevalence of JAK2 mutation in Essential Thrombocythemia patients, total (000s)
- Abbreviations and Acronyms used in the report
- USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- France Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- France Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- India Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- India Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.